about
Single high-dose oral vitamin D3 (stoss) therapy--a solution to vitamin D deficiency in children with cystic fibrosis?High burden of RSV hospitalization in very young children: a data linkage study.Association of rhinovirus with exacerbations in young children affected by cystic fibrosis: Preliminary data.Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain.Bacterial causes of empyema in children, Australia, 2007-2009.Cannabis smoking and respiratory health: consideration of the literature.Treatment of severe small airways disease in children with cystic fibrosis: alternatives to corticosteroids.Genetic contributions to rare childhood lung diseases.Are annual blood tests in preschool cystic fibrosis patients worthwhile?CareTrack Kids-part 1. Assessing the appropriateness of healthcare delivered to Australian children: study protocol for clinical indicator developmentCareTrack Kids-part 2. Assessing the appropriateness of the healthcare delivered to Australian children: study protocol for a retrospective medical record review.CareTrack Kids-part 3. Adverse events in children's healthcare in Australia: study protocol for a retrospective medical record reviewPaediatric prescribing of asthma drugs in the UK: are we sticking to the guideline?The role of communication in paediatric drug safety.Non-CF bronchiectasis: does knowing the aetiology lead to changes in management?Assessment of hypoxia in children with cystic fibrosis.Gene therapy for children with cystic fibrosis--who has the right to choose?Assessing the feasibility of a web-based registry for multiple orphan lung diseases: the Australasian Registry Network for Orphan Lung Disease (ARNOLD) experience.Risk factors associated with RSV hospitalisation in the first 2 years of life, among different subgroups of children in NSW: a whole-of-population-based cohort studyPulmonary cysts in early childhood and the risk of malignancy.Bronchiectasis secondary to primary immunodeficiency in children: longitudinal changes in structure and function.Childhood interstitial lung disease due to surfactant protein C deficiency: frequent use and costs of hospital services for a single case in Australia.The role of azithromycin in patients with cystic fibrosis.Update of faecal markers of inflammation in children with cystic fibrosis.Exhaled breath condensate in pediatric asthma: promising new advance or pouring cold water on a lot of hot air? a systematic review.Annual Review Clinic improves care in children with cystic fibrosis.Primary ciliary dyskinesia: overlooked and undertreated in children.Presentation of primary ciliary dyskinesia in children: 30 years' experience.Childhood interstitial lung disease: A systematic review.Non-cystic fibrosis bronchiectasis in childhood: longitudinal growth and lung function.Advances in the detection and management of cystic fibrosis related diabetes.Anxiety in youth with asthma: A meta-analysis.Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: a decade's experience.Protective factors for social-emotional well-being of refugee children in the first three years of settlement in Australia.Attentional Bias in Children with Asthma with and without Anxiety Disorders.Diagnosing cystic fibrosis-related diabetes: current methods and challenges.Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria.Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry.A population study of respiratory rehospitalisation in very preterm infants in the first 3 years of life.Rare disease registries: a call to action.
P50
Q28275519-D9791913-CE3B-4A82-AFE2-878254CF0D0EQ31029754-B11B7FF8-5E6F-49FE-A3B7-B79919E3B013Q31163357-D89B146D-A100-4595-BA73-D9DE91B80073Q33602084-8EE06E47-C0D4-4EF3-AFFD-C7166D02D45CQ34224472-7C240910-5B64-4170-9509-DC618A38C06EQ34420153-D7B70411-39ED-49DE-9EE0-4A9A48544A08Q34661825-996799A6-95ED-46A4-BECA-64FE06760EB1Q34674398-68D739FB-0E89-4645-9044-6F87A16A55A3Q35011430-997C7B94-8C6F-4574-9403-6B0A28C4FB92Q35332362-1727232A-80D7-4D29-B1D6-6D42854ECBD8Q35332403-E647AB95-6537-4C85-B204-5A7BBC451768Q35333040-BD2EA83E-2FD3-4F40-9BF3-985455976CBAQ36154051-A68ED0C1-D055-42FA-8D7F-79613DB9BACCQ36155425-7D143914-ABCD-4F3C-AB82-A61484D3BC1EQ36182492-A2D0E80B-4D7A-4BAE-B2E7-CE6A620FEC3EQ36294520-9DED36FF-892E-4C33-9459-5B24C41498E2Q36491414-E39F4330-FCF8-4934-97A6-1B55650BCF2FQ36810539-99288FC0-FC73-4A2B-BE70-B650CCC029E1Q37063662-4899A0EC-8F20-43DC-B272-312B2D600A3DQ37342939-8A9215E1-D170-48CB-8D88-DF0B84301A8AQ37513973-A5BB8A64-38A6-496D-BCB6-0EC8D3F98D61Q37715117-FB0DCE15-759F-4459-A1AC-689D89B44151Q37736704-100863CB-867C-45F0-88C0-86EE1D97AF07Q38044377-E2BD4966-25C0-4E93-8715-6C2E27CE0EEAQ38080830-5424F2AE-0095-43F3-9FFB-CD7FBD3D7505Q38148917-D7441E34-7B13-4BEA-BE38-81482517D21CQ38221413-A7BFC181-70BD-4EAF-BEF1-70FA81ED7FE2Q38289287-24727E01-AF7F-4803-A8D0-A917D2B81B36Q38452648-8D4BA753-C51B-4602-995E-6F5908ADB17FQ38452999-EDB5A2B3-F65D-4CDE-A2A2-CDD39FE7C4F5Q38531235-5B5D4FB1-AB35-4D28-983B-2CEB7CBF09E8Q38651130-028E9724-7957-4087-AF1A-7E4A40297E06Q38661868-A8EF14BE-282E-4149-B73A-706968FFF7D5Q38683473-5D7B494D-8ECB-44F2-81C4-0A61537E0ACDQ38773112-944B2E11-1E7A-4B86-88FA-EB8955E0BF4AQ38857042-331CCA46-A398-4869-A742-928EE64453D6Q39633151-E23E37E3-E122-4327-8123-8C71DA85EF0BQ39650450-FA27940F-50FC-405B-9DAE-61FEB88BD761Q39749614-0D0C0483-D374-4873-B990-85A6B5AABCB6Q40048299-6938BCA3-3F32-40EC-975E-0ACD12D00BDE
P50
description
researcher
@en
հետազոտող
@hy
name
Adam Jaffe
@ast
Adam Jaffe
@en
Adam Jaffe
@es
Adam Jaffe
@nl
type
label
Adam Jaffe
@ast
Adam Jaffe
@en
Adam Jaffe
@es
Adam Jaffe
@nl
prefLabel
Adam Jaffe
@ast
Adam Jaffe
@en
Adam Jaffe
@es
Adam Jaffe
@nl
P106
P1153
36796177900
P21
P31
P496
0000-0002-1963-5415